A phase II randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole Plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer.

Study Chair
Dr. Marco Colleoni, EIO, Milano Italy

Statistician
Christian Fesl, ABCSG, Vienna, Austria
Ray Lin, Genentech, South San Francisco, CA, USA


Study Manager:
Christiaan McEwen, Sarah Brothers

Lead Trial Coordinator:
Holly Shaw

Trial Coordinator:
Poonam Jani

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Trial Monitor
Barbara Ruepp

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
August 5, 2014

Targeted Accrual
330

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login